COMP <GO>
IDXX vs JNJ // EV/EBITDA & P/E VALUATION
IDEXX Laboratories Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: IDXX 5
— JNJ 9
▲ EV/EBITDA & P/E VALUATION LEADER: JNJ
LAST: $551.21 (-4.30%) • MKT CAP: $45.38B
valuation
31.1x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IDXX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IDXX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 61.80% | 67.90% | -6.10 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.60% | 25.50% | +4.10 | IDXX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 31.1x | 18.5x | +12.60 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 2.33% | 2.97% | -0.64 | JNJ | /fcf-yield <GO> |
| Operating Margin | 31.60% | 34.70% | -3.10 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 24.60% | 28.50% | -3.90 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 10.40% | 6.00% | +4.40 | IDXX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 20.99 | 5.59 | +15.40 | IDXX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | IDXX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 7.20% | -0.70 | IDXX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.4 | 60.4 | -7.96 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 1.08 | -0.19 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.8x | 23.0x | +16.80 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $45.38B | $662.49B | -$617.12B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IDXX REV | JNJ REV | IDXX GROSS % | JNJ GROSS % | IDXX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.30B | $94.19B | 61.8% | 67.9% | $1.06B | $19.70B |
| FY 2024 | $3.90B | $88.82B | 61.0% | 69.1% | $808.1M | $19.84B |
| FY 2023 | $3.66B | $85.16B | 44.0% | 44.0% | $741.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IDXX // BETA 0.89
JNJ // BETA 1.08